<DOC>
	<DOCNO>NCT00582426</DOCNO>
	<brief_summary>This study evaluate efficacy Octreotide LAR prevent chemotherapy-induced diarrhea ( regimens contain 5 fluorouracil , irinotecan capecitabine ) patient colorectal cancer .</brief_summary>
	<brief_title>Evaluation Octreotide LAR Prevention Chemotherapy-induced Diarrhea</brief_title>
	<detailed_description>Eligible patient diagnosis colorectal cancer , candidate adjuvant chemotherapy first-line chemotherapy metastatic disease regimen contain fluorouracil , capecitabine and/or irinotecan . Eligible chemotherapy regimen include Irinotecan , Leucovorin ( folinic acid ) , Fluorouracil ( IFL ) , Leucovorin , Fluorouracil , Irinotecan ( FOLFIRI ) , combination Irinotecan Capecitabine , Roswell Park regimen Mayo Clinic regimen , without Oxaliplatin , Bevacizumab Cetuximab . Patients receive Erlotinib , Tyrosine-kinase , Epidermal Growth Factor Receptor ( EGFR ) -inhibitors , eligible . The acute treatment diarrhea leave physician 's discretion group . Patients control arm treat without Octreotide LAR . Patients experimental arm receive first dose Octreotide LAR ( 30 mg ) chemotherapy initiation , addition minimum two identical monthly dos Octreotide LAR ( interval 28 day ) , chemotherapy discontinue maximum six dos Octreotide LAR , whichever occur first . Patient evaluation do cycle efficacy toxicity .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Inclusion criterion : 1 . Providing write informed consent 2 . Age 18 80 year ; 3 . Histological diagnosis colorectal cancer , presence metastatic disease prior systemic therapy metastatic disease ( prior adjuvant therapy allow complete 6 month long inclusion study ) ; 4 . Indication treatment , accord judgment investigator , chemotherapy regimen contain either 5FU , capecitabine , irinotecan ; regimen may also include oxaliplatin , bevacizumab , cetuximab ; 5 . A performance status 0 1 accord Eastern Cooperative Oncology Group ( ECOG ) scale 6 . Adequate organ function lab value within specific range 7 . Female patient childbearing potential must negative serum pregnancy test within 7 day prior registration ; 8 . Fertile patient ( male female ) must agree use acceptable method contraception avoid pregnancy duration study 3 month study termination ; 9 . No prior use octreotide formulation . Exclusion criterion : 1 . Use concomitant antineoplastic treatment , regimens contain either 5FU , capecitabine , irinotecan without oxaliplatin , bevacizumab , cetuximab ; 2 . Previous concomitant need radiotherapy abdomen pelvis ; 3 . Indication treatment , accord judgment investigator , erlotinib , gefitinib , panitumumab , EGFRinhibitors cetuximab ; 4 . A second malignancy ( except situ carcinoma cervix , situ carcinoma bladder , adequately treat basalcell squamouscell carcinoma skin , another malignancy treat 5 year prior enrollment without recurrence ) ; 5 . Any type condition lead chronic diarrhea , include , limited inflammatory bowel disease ( e.g. , ulcerative colitis Crohn 's disease ) , chronic diarrhea presume confirm infectious origin , irritable bowel syndrome ; 6 . Active uncontrolled concurrent medical condition , include , limited , unstable angina , congestive heart failure , coronary artery disease , hypertension , diabetes mellitus , hyper hypothyroidism ; 7 . Active ongoing systemic infection ; 8 . Serious uncontrolled psychiatric illness ; 9 . Ongoing pregnancy lactation ; 10 . Female patient pregnant lactating , childbearing potential would practice medically acceptable method birth control ; 11 . Lesions irradiate included site measurable disease . If measurable lesion previously irradiate patient include ; 12 . Use investigational agent within 30 day prior enrollment study foreseen use investigational agent study ; 13 . History chronic ( â‰¥ 30 nonconsecutive day ) use laxatives ; 14 . Concurrent use antidiarrheal agent ; 15 . Inability comply study protocol . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>diarrhea</keyword>
	<keyword>drug therapy</keyword>
	<keyword>octreotide</keyword>
	<keyword>fluorouracil</keyword>
	<keyword>irinotecan</keyword>
	<keyword>capecitabine</keyword>
	<keyword>prevention</keyword>
</DOC>